NovaScan Announces the Appointment of Two Luminary Advisors
Robert W. Cook, Ph.D. and Robert Zieserl will become Advisors to the company Chicago IL – October 22, 2024: NovaScan, a clinical stage oncology company based in Chicago, IL, announced the appointment of two luminary advisors who will assist the company as it advances...
Epredia and NovaScan Announce Intent for U.S. Distribution Agreement for MarginScanTM Device for Non-Melanoma Skin Cancer Detection
Avantik to Serve as Primary Distribution Partner Portsmouth, NH – May 2, 2024 – Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for...
NovaScan and Dr Paul Grippo Receive Competitive Award for Pancreatic Cancer Research
February 7, 2024 Chicago, IL: NovaScan, a clinical stage oncology company based in Chicago, today announced that a collaboration with Dr Paul Grippo, Associate Professor of Gastroenterology and Hepatology at the University of Illinois College of Medicine, has been...
NovaScan Participating in Multiple Conferences in Lung and GI
September 26, 2023, Chicago, IL: NovaScan, Inc. a clinical stage venture-backed oncology company, announced today that the company has had multiple abstracts accepted in upcoming leading medical conferences around the globe. These conferences include the following:...
NovaScan Announces Launch of its nsCanary™ Lung Trial at University of Chicago
Principal Investigator Dr Kyle Hogarth will lead the trial August 1, 2023, Chicago, IL – NovaScan, a clinical stage oncology company based in Chicago, announced that it has received IRB approval to commence a clinical trial involving lung cancer and the nsCanary™...
PHC Corporation and NovaScan, Inc. Launch Collaboration to Explore the Feasibility of a Device that Supports Non-melanoma Skin Cancer Detection
PHC Corporation (headquarters: Minato-ku, Tokyo, President: Nobuaki Nakamura, hereafter PHC) and NovaScan, Inc. (headquarters: Chicago, Illinois, CEO: Craig Davis, hereafter NovaScan) announce the launch of a collaboration through which they will seek to explore the...
NovaScan’s nsCanary™ Tech Platform Named One of Five Finalists in AGA’s Shark Tank Competition
Program Recognizes Groundbreaking Technologies that Change the GI Landscape [MARCH 2, 2023 – CHICAGO, IL] NovaScan, a clinical stage oncology company, has been selected by the American Gastroenterological Association (AGA) as a finalist in its annual Shark Tank...
NovaScan Announces the Launch of a Human GI trial for its nsCanary™ Cancer Detection Device
Jan 9, 2023, Chicago, IL – NovaScan, a clinical stage oncology company based in Chicago, announced that it has started a human GI clinical trial for its nsCanary™ device at Texas International Endoscopy Center (TIEC), led by Principal Investigator Isaac Raijman MD....